Research
Hormonal
Myostatin inhibitors (e.g., neutralizing antibodies, soluble receptor decoys) increase muscle mass and strength but are associated with significant side effects, limiting their current utility.
Myostatin inhibitors are investigational drugs that can increase muscle mass and strength but are currently limited by significant side effects like fatigue, confusion, and muscle contractions. They are not yet standard treatments.
ModerateQualifiesMEDIUM confidence
However, neutralizing antibodies such as MYO-029, AMG 74, LY2495655 or soluble receptor decoys such as ACE-11, ACE-031 seem to have substantial effects on muscle mass and strength, but unfortunately also display a number of side effects including urticarial, aseptic meningitis, diarrhea, confusion, fatigue as well as involuntary muscle contractions.
Why this rating
Described as 'investigational' and 'in clinical development' with reported side effects.
Source
Muscle Wasting and Sarcopenia in Heart Failure and Beyond: Update 2017
Jochen Springer et al. · ESC Heart Failure · 2017
DOI 10.1002/ehf2.12237
narrative_reviewCited 245×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Resistance exercise combined with nutritional support (protein/micronutrients) is the primary evidence-based intervention for increasing muscle mass and strength in sarcopenia, outperforming exercise alone.Good
- Testosterone administration increases muscle power and function, but its use is limited by potential side effects, particularly cardiovascular events and prostate malignancy risk, which vary by administration route.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →